Market Cap (In USD)
50.3 Million
Revenue (In USD)
-
Net Income (In USD)
-53.47 Million
Avg. Volume
6.28 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.0-7.92
- PE
- -
- EPS
- -
- Beta Value
- -0.4
- ISIN
- US45254E1073
- CUSIP
- 45254E107
- CIK
- 1790340
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Benjamin J. Zeskind M.B.A., Ph.D.
- Employee Count
- -
- Website
- https://immuneering.com
- Ipo Date
- 2021-07-30
- Details
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
More Stocks
-
NICK
-
SVM
-
600293
-
NITINCASTNitin Castings Limited
NITINCAST
-
BONZUNBonzun AB (publ)
BONZUN
-
TRS
-
BKIRFBlack Iron Inc.
BKIRF
-
NHHHFFuelPositive Corporation
NHHHF